A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (NCT03460977)
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment. Part 3, which is open for enrollment is seeking men who: * have Castration Resistant Prostate Cancer (CRPC) and * have previously received treatment for CRPC and have progressed from the last treatment All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort). In the assessment phase: * participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods. * participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule. * participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule. After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding. The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.
Who can join: Review the eligibility criteria below.
Location: Banner-University Medical Center Tucson — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (84 Sites)
Showing the first 25 of 84 sites.
- Banner-University Medical Center Tucson — Tucson, Arizona
- The University of Arizona Cancer Center-North Campus — Tucson, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
- Arizona Urology Specialists, PLLC — Tucson, Arizona
- Pacific Cancer Medical Center INC — Anaheim, California
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- City of Hope Investigational Drug Services (IDS) — Duarte, California
- Norwalk Hospital — Norwalk, Connecticut
- The University of Kansas Cancer Center, Investigational Drug Services — Fairway, Kansas
- The University of Kansas Clinical Research Center — Fairway, Kansas
- The University of Kansas Hospital — Kansas City, Kansas
- The University of Kansas Medical Center Medical Office Building — Kansas City, Kansas
- The University of Kansas Cancer Center - Indian Creek Campus — Overland Park, Kansas
- The University of Kansas Cancer Center — Westwood, Kansas
- Norton Cancer Institute - Downtown — Louisville, Kentucky
- Norton Cancer Institute, Norton Healthcare Pavilion — Louisville, Kentucky
- Norton Hospital — Louisville, Kentucky
- Maryland Oncology Hematology, P.A. — Rockville, Maryland
- Brigham and Women's Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- Dana Farber Cancer Institute- Chestnut Hill — Newton, Massachusetts
- Oncology Hematology West, PC dba Nebraska Cancer Specialists — Omaha, Nebraska
- Hackensack University Medical Center — Hackensack, New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
- OU Health University of Oklahoma Medical Center — Oklahoma City, Oklahoma
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Explore by condition: All Metastatic Castration Resistant Prostate Cancer (mCRPC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.